Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - Cervarix, October 7, 2009 with Attachment

Submission Type: Original Application   Submission ID:  125259/0    Office: OVRR  


Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant


GlaxoSmithKline Biologicals          

Telecon Date/Time:  07-OCT-2009 12:22 PM                Initiated by FDA?  Yes

Telephone Number:    

Communication Categorie(s):



Telecon Summary:

Response to Clinical IR

FDA Participants:  

Non-FDA Participants:   

Trans-BLA Group: N    

Related STNs:  None

Related PMCs:  None

Telecon Body:

From: []
Sent: Wednesday, October 07, 2009 12:22 PM
To: Gemignani, Helen S
Cc: Cynthia.A.D';
Subject: Re: Cervarix - PMC - Submission of Final Clinical Study Report Dates

Dear Helen,
GSK agrees to commit to submitting the final clinical study reports for the long-term efficacy studies listed in your mail. Please find in the attachment the timings we would propose for the submission of these reports, except for HPV-009. As you know, HPV-009 is under NCI supervision, therefore we are checking with them before committing to timings for this study. We expect to have the details for HPV-009 tomorrow.
If you have any questions on the other studies, please don't hesitate to ask.
Thanks and best regards,



Attachment - Timings for Efficacy Studies

Page Last Updated: 04/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English